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Male Sprague Dawley rats were exposed to 2,3,4,6-tetrachlorophenol (TCP) for 5 days, 2 weeks, 4 weeks, or 13 weeks. TCP was
administered by gavage at doses of 0, 10, 25, 50, 100, or 200mg/kg/day. Endpoints evaluated included clinical observations, body
weights, liver weights, serum chemistry, blood TCP, gross pathology, and liver histopathology. There were no TCP exposure-
related clinical signs of toxicity. Mean body weight decreased 12–22% compared to control in the 100 and 200mg/kg/day groups.
Serum ALT concentrations were increased in rats of the 200mg/k/day. Liver weight increases were both dose- and exposure time-
related and statistically signiﬁcant at ≥25mg/kg/day. Incidence and severity of centrilobular hepatocytic vacuolation, hepatocyte
hypertrophy, and single cell hepatocytic necrosis were related to dose and exposure time. Following 13 weeks of exposure, bile
duct hyperplasia and centrilobular and/or periportal ﬁbrosis were observed in rats primarily of the highest TCP dose group. Blood
TCP concentrations increased with dose and at 13 weeks ranged from 1.3 to 8.5µg/mL (10 to 200mg/kg/day). A NOAEL of
10mg/kg/day was selected based on the statistically signiﬁcant incidence of hepatocyte hypertrophy at doses ≥25mg/kg/day.
1.Introduction
Chlorophenols are toxic to a wide range of organisms and,
therefore, are manufactured primarily to be used as bacteri-
cides, insecticides, or fungicides in a variety of commercial
products. For example, mixtures of pentachlorophenols
and tetrachlorophenols, including the chemical 2,3,4,6-
tetrachlorophenol (TCP) (CAS number 58-90-2), are used
at sawmills as wood preservatives [1–3]. Routes of potential
human exposure of chlorophenols are dermal contact,
inhalation, and ingestion. Urinary concentrations of pen-
tachlorophenol (PCP) and TCP have been observed in
woodworkers exposed to wood preservative mixtures of PCP
and TCP [4]. Nonoccupationally exposed humans in regions
of Finland had trace amounts of TCP in adipose and liver tis-
sues [5]. TCP has a relatively high octanol-to-water partition
coeﬃcient causing a concern for bioaccumulation. Soil and
downstream water samples from contaminated sawmill sites
contain chlorophenols, including TCP [3, 6]. Chlorophenols
have been detected in chlorinated drinking water and city
air. The U.S. Environmental Protection Agency (EPA) has
issued recommendations for drinking water concentrations
of several chlorophenols. The recommendation for TCP in
drinking water is 1ppb, though extensive investigation of the
health eﬀects of TCP has not been performed. A thorough
summary of health eﬀects of chlorophenols, including TCP,
in humans and laboratory animals was published by the
Agency for Toxic Substances and Disease Registry (ATSDR)
in 1999 [7].
Acute and subchronic oral toxicity studies in rats using
TCP were conducted by Hattula et al. [8]. Acute gavage
doses ranged from 300 to 632mg/kg (TCP dissolved in olive
oil), and subchronic (7 days/week for 55 days) doses ranged
from 10 to 100mg/kg/day. Multiple tissues were collected
at necropsy and examined microscopically. Results indi-
cated that the most adverse histopathological changes were2 Journal of Toxicology
observed in the liver following either single or repeated doses
of TCP. Liver eﬀects were dose dependent and ranged from
mild (mild proliferation of the bile canaliculi and occasional
necrosisofcellsofthecanaliculiandhepatocytes)tomedium
(focal areas of necrosis, large basophilic hepatocytes, and
gathering of polymorphonuclear leukocytes) to severe (large
conﬂuentnecrosiscoveringmostoftheliverparenchymaand
dilated veins) in severity. Inﬂammation of hepatic bile ducts
was also observed. EPA conducted a 90-day oral toxicity
study in Sprague Dawley (SD) rats using TCP doses of 0, 25,
100, or 200mg/kg/day [9]. Liver weights were increased and
centrilobular hypertrophy was observed in rats of the two
highest TCP doses. A NOAEL of 25mg/kg/day was selected.
Developmental toxicity studies in SD rats indicated
that TCP (puriﬁed or commercial grade) was fetotoxic
(delayed ossiﬁcation of the skull bones) at an oral dose of
30mg/kg/day,butnotteratogenic[10].ANOAELforembry-
otoxicity was 10mg/kg/day. A second developmental toxicity
study in SD rats was conducted by EPA and used oral TCP
doses of 0, 25, 100, or 200mg/kg/day [11]. Maternal weight
gain was reduced at 200mg/kg/day, but embryofetal growth,
prenatal viability, and fetal development were not adversely
aﬀected. Genotoxicity results of TCP were mixed showing
both positive and negative ﬁndings in several in vitro assays
[7]. Oxidative stress [12] and the absence or presence of
microsomal activation enzymes [13] were likely contributing
factors to uncertainty of a direct mutagenic eﬀect. Based on
results of Kitchin and Brown [14] who administered acute
oral doses of TCP in rats, TCP may be a weak promoter.
Ahlborg and Larsson [15] investigated the metabolism of
three tetrachlorophenols (including the 2,3,4,6-isomer) in
rats following intraperitoneal administration and identiﬁed
hydroquinone metabolites in the urine. The majority of the
TCP dose (96%) was excreted unchanged in the urine [15].
TCP is a metabolite of PCP and chlorobenzenes, such as
pentachlorobenzene [16, 17].
Currently, TCP is listed in the Integrated Risk Informa-
tion System (IRIS) database with a chronic oral reference
dose (RfD) of 0.03mg/kg/day [18]. The critical noncarcino-
geniceﬀectsusedforthepointofdepartureincalculatingthe
RfD were increased liver weights and centrilobular hypertro-
phy. The objective of this study was to focus on liver toxicity
associated with oral TCP exposure and characterize both the
dose response and time course relationships. The choice of
liver toxicity was due to its selection as the critical eﬀect in
the noncancer IRIS risk assessment. Previous studies with
TCP had not fully characterized the temporal relationship
of the progression of liver eﬀects especially at TCP doses
that included and extended beyond (both below and above)
previously reported NOAEL and LOAEL doses. Five doses of
TCP and 4 time points were selected to assess liver toxicity
in male Sprague Dawley rats. Endpoints evaluated included
clinical observations, body weights, liver weights, serum
chemistry, gross pathology, and liver histopathology. In
addition, blood samples collected at necropsy were analyzed
for TCP. Information gained from this study will be used to
inform selection of the critical adverse eﬀect of TCP, evaluate
its progression, and select a NOAEL.
2.MaterialsandMethods
2.1. Test Materials. 2,3,4,6-tetrachlorophenol (CAS No. 58-
90-2), 98% purity, was obtained from International Lab-
oratories USA (Catalog No. 1618611). Olive oil (CAS No.
8001-25-0) was obtained from VWR Scientiﬁc (Radnor, PA;
Catalog number 95034-796). Both test materials were stored
at room temperature until use.
2,3,4,6-tetrachlorophenol (TCP) purity was veriﬁed by
analysis of the neat compound dissolved in hexane using gas
chromatography with ﬂame ionization detection (GC/FID).
Compound purity was calculated to be >99.9% TCP. Qual-
itative analysis of the parent compound was conducted by
GC/mass spectrometry (MS) (Agilent 6980 GC coupled to
an Agilent 5973 MS) in an attempt to identify any impu-
rities present. Observed impurities included multiple tetra-
chlorophenol isomers (minor), trichlorophenol (minor),
and 3-4 chlorinated compounds which were not identiﬁed
by the mass spectral library database (trace).
2.2. Study Design, Animals, and Animal Husbandry. The
Hamner Institutes for Health Sciences is fully accredited
by the Association for Assessment and Accreditation of
LaboratoryAnimalCareInternational(AAALAC).Currently
acceptablepracticesofgoodanimalhusbandrywerefollowed
per National Research Council’s Guide for the Care and Use
of Laboratory Animals [19] and were in compliance with
all appropriate parts of the Animal Welfare Act regulations
[20, 21]. In addition, the study design and protocol were
approved by The Hamner Institutes’ Institutional Animal
Care and Use Committee (IACUC) prior to the initiation of
study.
Two hundred and forty-ﬁve 4-5-week-old male Sprague
Dawley rats (Rat/Crl:CD(SD)) from Charles River Laborato-
ries (Raleigh, NC) were used in this study (Table 1). An addi-
tional one or two rats were assigned to the control group per
time point to be used to assure a group size of at least 10 for
evaluation of biological endpoints. Upon arrival, rats were
acclimatedtohousingandanimalroomenvironmentfor12–
14 days. Rats were weighed and randomized using Provantis
8 (Provantis, Conshohocken, PA) to ensure that mean body
weight in each treatment group was approximately the same.
Animals were ear-tagged and housed 2 or less rats per cage
in shoebox style cages separated by treatment group. Alpha-
dri cellulose bedding (Shepard Specialty Papers, Kalamazoo,
MI) was used. Animals had access to reverse osmosis water
(Hydro Systems, Durham, NC) and pellet NIH-07 certiﬁed
feed (Zeigler Brothers, Gardners, PA) ad libitum. The animal
room was kept within the standard temperature and relative
humidity parameters (64 to 79◦F and 30 to 70% relative
humidity) and standard light cycle (0700–1900 hours).
2.3. Preparation and Administration of TCP. Doses of TCP
selected for study were 0, 10, 25, 50, 100, and 200mg/kg/day.
Dose selections were similar to those used in EPA’s 90-
day oral gavage study in Sprague-Dawley rats [9]o f0t o
200mg/kg/day but extended lower (10mg/kg/day) to assure
a NOAEL dose group and to be in agreement with IRIS [18]
point of departure dose level of 25mg/kg/day for derivingJournal of Toxicology 3
Table 1: Study design showing number of male SD rats assigned per TCP dose group and time point.
Time point (animal necropsy) TCP dose (mg/kg/day)1
02 10 25 50 100 200
5 d a y s 1 11 01 01 0 1 0 1 0
2 weeks 11 10 10 10 10 10
4 weeks 11 10 10 10 10 10
1 3 w e e k s 1 21 01 01 0 1 0 1 0
1TCP doses were prepared in olive oil vehicle and administered daily, 7 days/week.
2Olive oil only.
an oral reference dose (RfD). Dose selections did not exceed
200mg/kg/day, since TCP-exposure-related depression of
body weights was observed at 200mg/kg/day in the EPA
study [9].
Dosing solutions of TCP were prepared in olive oil and
administered by oral gavage at a volume of 5mL/kg body
weight. Dosing solutions were prepared weekly (approxi-
mately) and submitted for analysis on the same day they
were prepared. Upon receipt, dosing solutions were diluted
in triplicate with a suﬃc i e n ta m o u n to fn a n o g r a d eh e x a n e
(Mallinckrodt, St.Louis, MO) to allow the theoretical dose
concentrations to fall within a freshly prepared calibration
curve. The TCP calibration curve was prepared in olive oil
and diluted to a ﬁnal concentration range of 45 to 270µg/mL
with hexane. Samples and standards were analyzed by
GC/FID using a 60m × 320µm × 0.25µm Restek Rtx-1
column (Restek, Bellefonte, PA) and helium as the carrier
gas. Analysis was carried out in split mode (3:1) with a
totalﬂowrateof11.0mL/minandaninjectortemperatureof
250◦C.TheGCtemperaturegradientusedwasasfollows:(1)
initialtemperaturewasheldat150◦Cfor1min;(2)following
the 1min hold, the temperature was ramped up at 25◦C/min
until the ﬁnal temperature of 300◦C was obtained; (3) the
ﬁnal temperature was held for 4min for a total analysis time
of 11min. Chromatograms were manually integrated and
dosing solution concentrations were calculated through the
use of the generated calibration curves and dilution factors.
Dosing solution stability for TCP was conducted at two
concentrations, 2 and 40mg/mL in olive oil, and under
three diﬀerent environmental conditions. Aliquots of the
prepared doses were stored at (1) room temperature, (2)
room temperature and covered in aluminum foil, or (3) 4◦C
and covered in aluminum foil. Sub-samples of the aliquots
were analyzed by GC/FID following dilution with hexane
(ﬁnal concentration of 100 and 200µg/mL after dilution)
and quantiﬁed through comparison to a freshly prepared
calibrationcurve(describedpreviously).Sampleanalysiswas
conducted every week for a total of 4 weeks (4 total analyses
including time 0). Following completion of the stability
studies, it was observed that the concentration of TCP in
olive oil stored under cold storage conditions decreased
slightly more than the TCP concentrations stored under the
other two conditions. However, all three storage conditions
were still within ±10% of the original time 0 concentration.
The mean ± standard deviation of the weekly dosing
solutions was 2.0 ± 0.1, 4.7 ± 0.8, 9.7 ± 1.3, 19.5 ± 3.6, and
39.1±2.4mg TCP/mL corn oil for target concentrations of 2,
5, 10, 20, and 40mg TCP/mL olive oil, respectively. Animals
were orally gavaged with 5mL of dosing solution/kg body
weight resulting in weekly mean analytical doses of 10.0,
23.5, 48.5, 97.5, and 195.5mg TCP/kg body weight. Control
animals received 5mL/kg body weight olive oil vehicle only.
Gavage exposure occurred in the morning, 7 days/week, for
the selected time period (Table 1).
2.4. Mortality Checks, Clinical Observations, Body Weights,
and Organ Weights. Animals were checked daily for clinical
signs of toxicity, morbidity, or death. Body weights were
measured daily just before gavage dosing and prior to
scheduled necropsy. At necropsy, the liver was removed and
weighed. Clinical observations, body weights, and organ
weights were recorded in Provantis 8.
2.5. Necropsy, Serum Clinical Chemistry, Blood TCP Analysis,
and Tissue Histopathology. Animal necropsies occurred on
scheduled days (Table 1) within a few hours following the
administration of TCP (or olive oil for controls). Animals
were weighed and anesthetized with a lethal intraperitoneal
injection of sodium pentobarbital. A cardiac puncture was
performed to collect blood samples, and the animal was
then exsanguinated via transection of the abdominal aorta.
Blood samples were placed in a serum separator tube (gel
barrier) and centrifuged for clinical chemistry analysis. The
following analytes were measured in the serum within a
few hours of collection: aspartate aminotransferase (AST),
alanineaminotransferase(ALT),alkalinephosphatase(ALP),
bilirubin (total), and lactate dehydrogenase (LDH). Reagent
sets for the serum analytes and quality control (QC)
materials, including standards were obtained from Pointe
Scientiﬁc, Inc. (Canton, MI). Instructions supplied with
the reagent sets were followed. A Roche COBAS FARA II
chemistry analyzer was used for analysis of serum samples.
The COBAS operator manual and laboratory standard
operating procedures (SOPs) were followed for conducting
analyte analyses.
Another aliquot of at least 0.5mL of blood was col-
lected from at least 5 animals per dose per time point
(animals selected randomly), placed in an anticoagulated
tube(EDTA),andstoredinafreezer(−80◦C).Thesesamples
were analyzed for TCP concentration using GC with electron
capture detection (GC/ECD). Aliquots (250µL) of thawed
whole blood samples were mixed with 250µL of saturated
sodium chloride solution and 10µL of internal standard4 Journal of Toxicology
solution (Lindane in methanol at 25µg/mL). Samples were
then extracted with 500µL of hexane, brieﬂy vortexed,
placed on a sample rotator for 30min at room temperature,
and allowed to sit for 5min prior to centrifugation at
8000 × G for 5min. The top hexane layer was removed
and transferred to a GC sample vial for analysis. Calibration
curve samples were prepared by spiking whole blood with
known amounts of TCP to a range of 1.9 to 24µg/mL. The
limit of quantitation for TCP was below 0.3µg/mL blood.
Samples and standards were analyzed on a 30m × 320µm ×
0.25µm Restek Rtx-1 column using helium as the carrier gas.
Instrumentalanalysiswascarriedoutinsplitlessmodewitha
total ﬂow rate of 8.5mL/min and an injector temperature of
250◦C.TheGCtemperaturegradientusedwasasfollows:(1)
initialtemperaturewasheldat150◦Cfor1min;(2)following
the 1min hold, the temperature was ramped up at 25◦C/min
until the ﬁnal temperature of 300◦C was obtained; (3) the
ﬁnal temperature was held for 4min for a total analysis time
of 11min. Chromatograms were manually integrated and
dosing solution concentrations were calculated through the
use of the generated calibration curves and dilution factors.
Following gross examination for abnormalities, a slice
from 3 of the 4 liver lobes (median, right, and left) was
placedinalabeledcassette.Theliverlobeswerenotevaluated
independently to identify or assess interlobe variability but
were evaluated together to characterize an overall hepatic
eﬀect of TCP exposure. The cassette was placed into a 10%
neutral buﬀered formalin cup for approximately 48 hours.
The cassette was then transferred to a cup containing 70%
ethanol followed by paraﬃn embedding. Liver-embedded
cross sections (5um) were stained with hematoxylin and
eosin for microscopic evaluation by a board-certiﬁed pathol-
ogist. Histopathology observations were ranked based on
the following severity score: 1, minimal; 2, slight/mild; 3,
m o d e r a t e ;4 ,m o d e r a t e l ys e v e r e ;a n d5 ,s e v e r e / h i g h .A n
average severity score was calculated by totaling the severity
scores for an observation at a speciﬁed exposure site for an
exposure cohort and dividing by the total number of animals
aﬀected.
2.6. Statistical Analysis. Body weight and organ weight data
were analyzed using the statistical module of the Provantis
software data collection system (NT2000 versions 8.2.0.1 or
8.2.0.6, Instem, Coshohoken, PA). A one-way analysis of
variance (ANOVA) test followed by a Dunnett’s test was
used to compare the control group with TCP exposure
groups at each time point. Serum chemistry data were
analyzed using JMP 9.0.0 software (SAS Institute, Inc., Cary,
NC). A goodness of ﬁt test (Shapiro-Wilk, P<0.01) and
homogeneity of variances test (Levene’s, P<0.05) were
conducted. If pretest assumptions were met, an ANOVA was
used and, if signiﬁcant (P<0.05), TCP-exposed groups
werecomparedtothecontrolgroupusingDunnett’stest.For
data sets of nonnormal distributions or unequal variances,
a Welch ANOVA followed by Steel’s test was used. For
incidence data (histopathology), a Fisher’s exact test (one
tail) was done comparing each TCP dose group to the
corresponding control group and applying the Bonferroni
correction to P values. A result of P<0.05 was considered
signiﬁcant.
3. Results
3.1. Clinical Observations and Body Weights. There were
no TCP exposure-related clinical signs of toxicity during
the study. Statistically signiﬁcant decreases were observed
in mean body weights of rats of the 200mg/kg/day group
compared to controls beginning week 7 of dosing. By study
week 13, the mean body weight was 22% lower than control
animals. Mean body weights were also reduced in animals
of the 100mg/kg/day group compared to control and were
statistically signiﬁcant during the last 3 weeks of dosing
(study weeks 11, 12, and 13). By study week 13, the mean
body weight was 12% lower in the 100mg/kg/day group
compared to control animals. Mean body weights of rats of
the 50mg/kg/day group were mildly reduced (6%) compared
to controls during the study, but these reductions were
not statistically signiﬁcant. Mean body weights were similar
betweencontrolandTCPexposuregroupsof ≤25mg/kg/day
throughout the study. Individual and group mean body
weights for all animals on study at each scheduled necropsy
are provided in Supplemental Table 1 in Supplementary
Material available online at doi:10.1155/2012/376246.
3.2. TCP in Blood. Blood samples for TCP analysis were
collected approximately two hours after dosing at each time
point. Blood TCP concentrations increased with dose. For
example, at 13 weeks, mean TCP blood concentrations were
1.3, 2.2, 5.3, 8.7, and 8.5µg/mL for TCP dose groups of 10,
25, 50, 100, and 200mg/kg/day, respectively (Table 2). Mean
TCP blood concentrations were lower after 4 or 13 weeks
exposure, compared to TCP blood concentrations following
5d a y so r2w e e k se x p o s u r e( Table 2).
3.3. Serum Chemistry. Statistically signiﬁcant increases in
mean ALT in the 200mg/kg/day group compared to control
valueswereobservedfollowing2,4,and13weeksofexposure
(Table 3). At 13 weeks, ALT was also increased in the 50 and
100mg/kg/day exposure groups. Increases in mean ALP and
AST were also observed in the 200mg/kg/day group at 13
weeks (P<0.01), but not at other exposure time points or in
lower TCP dose groups (≤100mg/kg/day) (Table 3). There
were no TCP exposure-related increases in LDH and total
bilirubin compared to control values throughout the study
(data not shown).
3.4. Organ Weights. At TCP doses ≥100mg/kg/day, sta-
tistically signiﬁcant increases in absolute and relative (to
body weight) mean liver weights compared to controls were
observed in rats at all time points (Table 4). As early as 5
day exposure, statistically signiﬁcant increases in absolute
and relative mean liver weights were observed in the 100
and 200mg/kg/day groups. Signiﬁcant increases in mean
liver weights were observed in the 50mg/kg/day group
following 2-, 4-, or 13-weeks exposure. Mean liver weights
weresigniﬁcantlyincreasedinratsofthe25mg/kg/daygroupJournal of Toxicology 5
Table 2: Blood TCP concentration (µg/mL) in male SD rats following 5 days, 2 weeks, 4 weeks, and 13 weeks of daily exposure of TCP by
oral gavage.
Time point TCP dose (mg/kg/day)
0 10 25 50 100 200
5d a y s 0 .0 ±0.01 0.8 ±0.12 .8 ± 0.96 .6 ± 2.79 .5 ±2.61 9 .6 ±5.7
2w e e k s 0 .0 ±0.01 .2 ±0.46 .7 ± 1.61 1 .3 ± 5.42 14.0 ±1.71 6 .7 ±2.0
4w e e k s 0 .0 ±0.00 .8 ±0.52 .3 ± 1.05 .6 ± 2.38 .0 ±2.71 5 .4 ±4.4
13 weeks 0.0 ±0.01 .3 ±0.72 .2 ± 0.75 .3 ± 1.78 .7 ±2.98 .5 ±2.0
1Values are mean ± standard deviation (n = 5).
2n = 6.
Table 3: Select serum chemistry concentrations (IU/L) of male SD rats following 5 days, 2 weeks, 4 weeks, and 13 weeks of daily exposure
of TCP by oral gavage.
Time point Analyte TCP dose (mg/kg/day)
0 10 25 50 100 200
5D a y s
ALP1 621 ±2044 515 ±205 681 ±212 585 ±163 610 ±106 761 ±178
ALT2 40 ±83 5 ±10 38 ±11 41 ±12 41 ±20 50 ±15
AST3 118 ±14 109 ±36 116 ±36 118 ±25 129 ±33 126 ±31
2W e e k s
ALP 511 ± 219 537 ±140 555 ±146 564 ±209 566 ±187 653 ±120
ALT 40 ± 13 40 ±11 52 ±51 31 ±11 42 ±13 68 ±21
∗∗
AST 126 ±56 127 ±42 137 ±83 116 ±51 132 ±36 144 ±18
4W e e k s
ALP 407 ±128 500 ±140 463 ±118 489 ±98 530 ±180 523 ±123
ALT 43 ± 93 9 ±83 9 ±93 8 ±84 7 ±10 57 ±10
∗
AST 122 ±23 134 ±20 129 ±25 119 ±14 123 ±11 124 ±13
13 Weeks
ALP 304 ± 83 295 ±102 396 ±153 357 ±115 425 ±115 585 ±127
∗∗
ALT 38 ±14 42 ±95 7 ±52 61 ±39
∗ 63 ±29
∗ 120 ±47
∗∗
AST 125 ±24 130 ±17 137 ±21 152 ±45 151 ±22 244 ±59
∗∗
1ALP: alkaline phosphatase.
2ALT: alanine aminotransferase.
3AST: aspartate aminotransferase.
4mean ± standard deviation for n = 10 except for the following groups: n = 9 (25 and 50mg/kg/day, 13 weeks); n = 11 (0mg/kg/day, 5 days, 2 weeks, and 4
weeks); n = 12 (0mg/kg/day, 13 weeks).
∗P<0.05 compared to control.
∗∗P<0.01 compared to control.
Table 4: Absolute and relative (to body weight) liver weights of male SD rats following 5 days, 2 weeks, 4 weeks, and 13 weeks of daily
exposure of TCP by oral gavage.
Time point Liver weight TCP dose (mg/kg/day)
0 10 25 50 100 200
5D a y s g1 13.1 ±1.13 13.4 ±1.71 3 .5 ±1.31 3 .1 ±2.01 5 .6 ±1.7∗∗ 16.1 ±1.4∗∗∗
%2 4.36 ±0.20 4.44 ±0.29 4.48 ±0.35 4.58 ±0.37 5.16 ±0.67∗∗∗ 5.48 ±0.32∗∗∗
2W e e k s g1 3 .8 ±1.51 5 .2 ±1.31 5 .9 ±1.7∗ 17.9 ±2.1∗∗∗ 19.5 ±1.8∗∗∗ 21.4 ±2.3∗∗∗
%3 .89 ±0.24 4.25 ±0.27∗ 4.43 ±0.25∗∗∗ 4.96 ±0.34∗∗∗ 5.56 ±0.23∗∗∗ 6.36 ±0.32∗∗∗
4W e e k s g1 6 .0 ±3.31 6 .4 ±2.11 7 .4 ±2.62 0 .0 ±3.7∗ 23.2 ±2.0∗∗∗ 25.4 ±4.8∗∗∗
%3 .90 ±0.68 3.86 ±0.24 4.23 ±0.28 4.73 ±0.49∗∗ 5.75 ±0.32∗∗∗ 6.54 ±0.78∗∗∗
13 Weeks g1 6 .8 ±2.92 1 .4 ±2.72 4 .2 ± 3.3∗∗ 27.5 ±5.5∗∗∗ 33.6 ±7.3∗∗∗ 38.9 ±7.2∗∗∗
%3 .10 ±0.20 3.65 ±0.13 4.36 ±0.42∗∗∗ 5.46 ±0.62∗∗∗ 7.11 ±0.86∗∗∗ 9.40 ±1.11∗∗∗
1 g: grams.
2%: [liver weight/body weight] × 100.
3mean ± standard deviation for n = 10 except for the following groups: n = 9 (25mg/kg/day and 50mg/kg/day, 13 weeks); n = 11 (0mg/kg/day, 5 days, 2
weeks, and 4 weeks); n = 12 (0mg/kg/day, 13 weeks).
∗P<0.05 compared to control.
∗∗P<0.01 compared to control.
∗∗∗P<0.001 compared to control.6 Journal of Toxicology
Table 5: Selected histopathologic changes in the hepatocyte of male SD rats following 5 days, 2 weeks, 4 weeks, and 13 weeks of daily
exposure of TCP by oral gavage.
Time point Finding TCP dose (mg/kg/day)
0 10 25 50 100 200
5d a y s
Vac-C1 —6 — — ———
Hyp-C2 — — — — 1/10 (1.0) 10/10∗∗∗ (1.0)
Nec-C3 — — — — 1/10 (1.0) 2/10 (1.0)
2w e e k s
Vac-C — — 1/10 (1.0)7 1/10 (1.0) 4/10 (1.5) 7/10∗∗ (1.6)
Hyp-C — — — 4/10 (1.0) 10/10∗∗∗ (2.0) 10/10∗∗∗ (3.4)
Nec-C — — — 2/10 (1.0) 6/10∗ (1.0) 9/10∗∗∗ (2.3)
4w e e k s
Vac-C — 1/10 (1.0) 4/10 (1.3) 7/10∗∗ (1.4) 9/10∗∗∗ (1.7) 8/10∗∗ (1.6)
Hyp-C — — 4/10 (1.0) 10/10∗∗∗ (1.0) 10/10∗∗∗ (2.2) 10/10∗∗∗ (3.5)
Nec-C — — — 7/10∗∗ (1.0) 9/10∗∗∗ (1.3) 9/10∗∗∗ (2.4)
13 weeks
Vac-C 4/12 (1.0) 9/10 (1.6) 9/9∗ (2.4) 9/9∗ (3.4) 10/10∗∗ (4.3) 10/10∗∗ (4.7)
Hyp-C — 4/10 (1.0) 8/9∗∗∗ (1.3) 9/9∗∗∗ (2.6) — —
Hyp-D4 — — — — 10/10∗∗∗ (3.0) 10/10∗∗∗ (4.2)
Nec-C — — — 3/9 (1.0) 2/10 (1.5) —
Nec-M5 — — — — 1/10 (1.0) 10/10∗∗∗ (2.3)
1Vac-C: vacuolation (centrilobular).
2Hyp-C: hypertrophy (centrilobular).
3Nec-C: necrosis, single cell (centrilobular).
4Hyp-D: hypertrophy (diﬀuse).
5Nec-M: necrosis, single cell (midzonal).
6— indicates no ﬁnding.
7Incidence:numberwithﬁnding/numberexamined(averageseverityscorewhere1:minimal,2:slight/mild,3:moderate,4:moderatelysevere,5:severe/high).
∗P<0.05 compared to control.
∗∗P<0.01 compared to control.
∗∗∗P<0.001 compared to control.
following 2 and 13 weeks of TCP exposure. At the 2-week
necropsy, relative liver weights were increased (P<0.05)
compared to controls in rats of the 10mg/kg/day group,
but at no other time point (Table 4). The liver weight
increases were both TCP dose dependent and exposure time
dependent (Table 4). For example, at the 4-week necropsy,
the mean relative liver weights, expressed as percentage of
control, were 99%, 108%, 121%, 147%, and 168% for the
10,25,50,100,and200mg/kg/daygroups,respectively.At13
weeks, percentage of control values was 118%, 141%, 176%,
229%, and 303% for the 10, 25, 50, 100, and 200mg/kg/day
groups, respectively. Individual animal liver weight data are
provided in Supplementalary Table 1.
3.5. Histopathology. At the scheduled necropsies, there were
isolated gross lesions observed in livers of a few TCP-exposed
animals that consisted of areas of pale appearance, dark
appearance, or at the 13-week sacriﬁce, a uniform brown
parenchyma.Thepaleappearancewasnotedinafewratsand
corresponded to scattered vacuolation. The dark appearance
was due to passive congestion in the liver and was not
diagnosed. Brown parenchyma of the liver was present in
80% of the rats of the 200mg/kg/day group at the 13-week
necropsy. This ﬁnding corresponded to moderately severe to
severe scoring of centrilobular hepatocytic vacuolation. The
remaining animals in the 200mg/kg/day group that did not
have the gross appearance of brown parenchyma also had
centrilobular hepatocytic vacuolation, but the score was less
severe.
TCP-related liver microscopic alterations that were
observed as early as 5 days exposure and gradually became
higher in incidence and more severe in appearance were
centrilobular hepatocytic hypertrophy and single cell hepa-
tocytic necrosis (Table 5). In the two highest doses of TCP,
the hypertrophy was diﬀuse and the single cell necrosis
was midzonal following 13 weeks of exposure (Figures
1 and 2). Centrilobular single cell necrosis and hepato-
cytic hypertrophy were also observed in animals of the
50mg/kg/day dose group after 2 weeks of exposure, but with
less incidence (20–40%) and severity (minimal) compared
to the two higher TCP dose groups. Single cell necrosis
was not observed in rats of ≤25mg/kg/day, but hepatocytic
hypertrophy was observed in rats of the 25mg/kg/day group
following 4 weeks or 13 weeks of TCP exposure (Figure 3
and Table 5). Four rats of the 10mg/kg/day group had
minimal hepatocytic hypertrophy, but the incidence was not
statistically signiﬁcantly diﬀerent compared to rats of the
control group.
As early as 2 weeks of exposure, centrilobular hepato-
cytic vacuolation was a consistent ﬁnding in TCP-exposed
rats of ≥25mg/kg/day. However, scattered or centrilobular
hepatocytic vacuolation was also observed in control rats
at the 4-week and 13-week necropsies. The incidence and
severity of vacuolation were greater in TCP exposure groupsJournal of Toxicology 7
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Figure 1: Normal liver (0mg/kg/day TCP following 13 weeks
exposure) showing uniform size and shape of hepatocytes around
the central vein (C) and portal area (P). H & E, 10x.
P
P
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50 µm
Figure 2: Liver (200mg/kg/day TCP following 13 weeks exposure)
characterized by marked hepatocellular hypertrophy and hepa-
tocellular vacuolation bridging from one centrilobular area (C)
to the next. Both the portal (P) and centrilobular veins (C) are
compressed. Single cell necrosis is indicated by arrows. H & E, 10x.
indicating exacerbation of this alteration with time and dose.
Hepatocytic vacuolation was the most prominent ﬁnding
in TCP-exposed rats at the 13-week necropsy. In rats of
the 200mg/kg/day group, hepatocytic vacuolation extended
well into the midzonal areas and formed bridges from
one centrilobular area to another (Figures 1 and 2). Less
severe hepatocytic vacuolation was noted at 25mg/kg/day
(Figure 3). Bile duct hyperplasia was observed with 100%
incidence in rats of the 200mg/kg/day group at 13 weeks;
incidence was 20% in rats of the 100 and 25mg/kg/day
groups (Figure 4). This change appeared to be a secondary
response to injury to the hepatocytes. Changes in the bile
canaliculi or sinusoids were not noted in any of the animals
examined. Incidences of 40 to 60% centrilobular and/or
periportalﬁbrosiswereobservedinratsofthe200mg/kg/day
group,and10%incidencewasobservedinratsofthe100and
25mg/kg/day groups (Figures 5 and 6).
Figure 3:Liver(25mg/kg/dayTCPfollowing13weeksofexposure)
characterized by mild hepatocellular hypertrophy and hepatocellu-
lar vacuolation around the central veins. H & E, 10x.
Figure 4: Liver (200mg/kg/day following 13 weeks of exposure)
characterized by diﬀuse hepatocellular hypertrophy, hepatocellular
vacuolation, and biliary ductal hyperplasia in the portal area. H &
E, 20X.
4. Discussion
In previous rodent oral gavage toxicity studies with TCP,
the liver was identiﬁed as the critical target organ of eﬀect
following acute or repeated exposure. Increases in liver
weights, serum ALP, ALT, bilirubin, and hepatic inﬂamma-
tion, hypertrophy, and necrosis were reported [8, 9]. The
results obtained in the current study are in agreement with
thesestudiesandprovidenoteworthynewinformationabout
dose and exposure duration related to TCP toxicity. For
example, body weight reduction and increased liver weights
were observed in rats of the highest dose groups (100 and
200mg/kg/day) in the current 13-week study and the EPA
90-day study [9]. In the current study, increased liver weights
were also observed in rats of lower TCP dose groups (50 and
25mg/kg/day) following 13 weeks of exposure, though this
result was not observed in rats dosed with 25mg TCP/kg/day
in the EPA study [9]. Serum ALT levels were elevated in male
ratsof the200mg/kg/day groupfollowing 13weeks exposure
(current study and EPA study [9]), but the current study
also showed an increase in serum ALT after 2 or 4weeks of
exposure at this dose and an increase in ALT in rats of the
50 and 100mg/kg/day groups after 13 weeks of exposure.8 Journal of Toxicology
Figure 5: Liver (200mg/kg/day following 13 weeks of exposure)
characterized by hepatocellular hypertrophy and hepatocellular
vacuolation, with vacuoles of varying sizes, around a central vein
which has early ﬁbrosis. H & E, 20x.
Figure 6: Liver (200mg/kg/day following 13 weeks of exposure)
characterized by hepatocellular hypertrophy and vacuolation, bil-
iary ductal hyperplasia, and periportal ﬁbrosis. H & E, 20x.
Serum ALP and AST were signiﬁcantly increased in rats
of the high-dose group at 13 weeks (Table 3), but this was
not completely consistent with ﬁndings in the EPA study
[9], where ALP increased in male rats of the 200mg/kg/day
group after 45 days of exposure only. Also, serum total
protein and albumin were increased in male rats of the 100
and 200mg/kg/day groups after 90 days of exposure [9].
Results of both current and EPA studies indicate that at
high doses of TCP (≥50mg/kg/day) serum markers of liver
injury were increased with ALT being the most consistent
marker of eﬀect. The lack of hepatocyte necrosis (Table 5,
TCP doses ≤ 25mg/kg/day, all time points) or mild degree
of necrosis (Table 5, TCP doses of 50 and 100mg/kg/day, all
timepoints)mayexplaintheabsenceorweakresponseofthe
serum enzyme ﬁndings (Table 3) .S e r u mA L P ,A L T ,a n dA S T
were signiﬁcantly increased at 200mg/kg/day following 13
weeks of exposure, and this observation correlated well with
the incidence (100%), degree (mild/moderate), and extent
(midzonal) of hepatocyte necrosis.
The most notable diﬀerence in results between the
current study and previous studies is the observation of
liver histopathology at lower TCP doses (≤25mg/kg/day).
Centrilobular hypertrophy and vacuolation were observed in
rats of the 10 and 25mg/kg/day groups (Table 5). However,
after 13 weeks of exposure, the severity of hypertrophy
was minimal in the 10mg/kg/day rats, and the incidence
was not statistically signiﬁcantly diﬀerent compared to the
control rats. Hepatocyte hypertrophy is typically observed
with enzyme induction; although Phornchirasilp et al. [22]
observed signiﬁcant increases in microsomal protein and
cytochrome P450 levels in Sprague-Dawley rats dosed with
4-chlorophenol, studies reporting TCP-induction of liver
metabolizing enzymes were not found suggesting that other
pathways may be involved in the hypertrophy response.
The observed hepatocyte vacuolation in conjunction with
hypertrophy (Table 5) may indicate perturbation of lipid
metabolism, a common sequel to hepatic injury. Although
speciﬁc lipid staining was not done in the present study, the
appearance and distribution of the vacuoles in the liver are
histologically consistent with lipid accumulation in injured
hepatocytes. Lipid accumulation could have a number of
causes although the most probable one is oxidative stress
andbiotransformationofTCPtoelectrophilicintermediates.
Ahlborg and Larsson [15] administered Sprague-Dawley rats
with TCP (i.p.) and identiﬁed trichloro-p-hydroquinone as
a minor urinary metabolite. Further, Arrhenius et al. [23]
reported disruption of microsomal detoxiﬁcation enzymes
by TCP, which may contribute to the initiation of free
radicals and lipid peroxidation in the liver. The most
obvious toxic mechanism associated with exposure of TCP
and related chlorophenols (e.g., pentachlorophenol) is the
uncoupling of mitochondrial oxidative phosphorylation
[24]. The higher substituted chlorophenols, such as TCP,
are more potent in uncoupling oxidative phosphorylation
than the monochlorophenols [25, 26]. Drugs or chemicals
that uncouple oxidative phosphorylation can produce liver
hypertrophy [27].
As e c o n dn o t a b l ed i ﬀerence in the histology of prior
studies compared to this one was that alterations in bile
canaliculi and diﬀuse necrosis of the liver described by
Hattula et al. [8] were not evident in the animals examined
on this study. Biliary changes were limited to bile duct
hyperplasia in the portal area. This change appeared to be
a secondary response due to injury to the hepatocytes. This
apparent diﬀerence in toxic hepatic response in the prior
study may be due to diﬀerences in rat strains or other
experimental parameters.
With respect to the time course of liver weights, serum
enzymes, and liver histopathology, the current study clearly
showed a progression of greater severity of eﬀect with
increaseinexposuredurationofTCP(Tables3,4,and5).For
example, statistically signiﬁcant increases of centrilobular
hepatocytic hypertrophy were observed at 200mg/kg/day
after 5 days of exposure, at ≥100mg/kg/day after 2 weeks of
exposure, at ≥50mg/kg/day after 4 weeks of exposure, and at
≥25mg/kg/day after 13 weeks of exposure (Table 5). Severity
also increased with time and by 13 weeks the hypertrophy
was diﬀused in the 200 and 100mg/kg/day groups (Table 5).
Centrilobular single cell necrosis gradually became midzonal
with time in the two highest dose groups. At 13 weeks,
bile duct hyperplasia and centrilobular/periportal ﬁbrosisJournal of Toxicology 9
were observed primarily in rats of the 200mg/kg/day group
(Figures 4, 5,a n d6). Hattula et al. [8]o b s e r v e dp r o l i f e r a t i o n
of the bile canaliculi in rats dosed with TCP and attributed
this alteration as a secondary process preceded by speciﬁc
parenchymal cell damage. Centrilobular vacuolation was
ﬁrst observed in rats of the mid- and higher-dose groups
(≥25mg/kg/day) after 2 weeks of exposure and became
prevalent in all TCP dose groups after 4 weeks of exposure.
However, at 13 weeks, minimal vacuolation was noted in
33% of the controls. The olive oil vehicle received by the con-
trol rats may be a contributing factor to this observation. In
the highest TCP dose groups, extensive bridging vacuolation
resulting in brown color to the liver parenchyma was noted
in rats during the 13-week necropsy.
In conclusion, male SD rats administered TCP by gavage
at doses up to 200mg/kg/day for up to 13 weeks had
mild liver eﬀects manifested as increased liver weights,
centrilobular hepatocytic single cell necrosis, hepatocyte
hypertrophy, and hepatocyte vacuolation. Both liver weight
increases and liver histopathology were dose related and
exposure duration dependent. A NOAEL of 10mg/kg/day
was selected based on the statistically signiﬁcant incidence
of hepatocytic hypertrophy at TCP doses ≥25mg/kg/day.
The NOAEL of 10mg/kg/day is in agreement with the
liver histopathology results reported by Hattula et al. [8],
but below the NOAEL of 25mg/kg/day selected by IRIS
[18] based on increased liver weights and centrilobular
hypertrophy at TCP doses ≥100mg/kg/day.
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